Monitor pricing and final share count when the offering prices; the overallotment option could add up to $747.5M total. The positive Q1 launch metrics and ACACIA-HCM data provide fundamental support, but near-term selling pressure from the offering may weigh on the stock.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $74.84entry
- T+1 · 6mo ago −0.73%α −0.40% · $74.29
- T+5 · 6mo ago −0.04%α −1.17% · $74.81
- T+20 · 6mo ago −5.52%α −8.30% · $70.71
- T+60 · 4mo ago +3.06%α +1.00% · $77.13
Price Chart
How similar events traded
Executive Summary
Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, with an option for an additional $97.5M. The filing comes on the same day as positive Q1 2026 results showing $4.8M in initial MYQORZO revenue and successful ACACIA-HCM trial results. Proceeds will fund the commercial launch and pipeline advancement, but the offering represents significant dilution.
Key Facts
- Aggregate public offering price of $650,000,000 for common stock
- Underwriters have 30-day option to purchase additional $97,500,000 in shares
- As of March 31, 2026, net tangible book deficit was $(826.6) million, or $(6.65) per share
- 124,237,823 shares outstanding as of March 31, 2026
- Proceeds intended for MYQORZO commercial launch, pipeline advancement, and general corporate purposes
- Directors and executive officers subject to 45-day lock-up agreements
- Q1 2026 MYQORZO net product revenue of $4.8 million from initial partial quarter
- Cash and investments of approximately $1.1 billion as of March 31, 2026
Financial Impact
$650 million offering represents approximately 8% dilution at current market cap, with proceeds strengthening cash position for commercialization
Risk Factors
- Significant dilution to existing shareholders
- Execution risk in commercial launch of MYQORZO
- Potential downward price pressure from at-the-market sales by underwriters
- Continued cash burn from R&D and commercialization activities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index-headers.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626.txt | 0001193125-26-206626 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers